8-K: Avalon GloboCare Secures $475,500 in Private Placement, Issues Shares and Pre-Funded Warrants

Avalon GloboCare Corp. has completed a private placement, raising $450,500 in net proceeds through the sale of common stock and pre-funded warrants to Brown Stone Capital Ltd., while also issuing shares from a note conversion.

Summary

• Avalon GloboCare Corp. (ALBT) entered into a Securities Purchase Agreement with Brown Stone Capital Ltd. on July 14, 2025.
• The company sold 121,200 shares of common stock and pre-funded warrants to purchase 354,300 shares of common stock.
• The total purchase price for these securities was $475,500.
• The transaction closed on July 17, 2025, with the company receiving net proceeds of $450,500 after deducting $25,000 in offering expenses for the investor's legal fees.
• A Registration Rights Agreement was also executed, obligating the company to register the shares and warrant shares.
• On July 15, 2025, the company issued 515,109 shares of common stock to a noteholder upon conversion of its note.
• As of July 15, 2025, the company's issued and outstanding common stock was 2,954,193 shares, excluding the newly issued shares and warrant shares from this private placement.

Sentiment

Score: 6

Explanation: The capital raise provides necessary funding and addresses debt, which is positive. However, the significant dilution from both the private placement and a separate note conversion, along with the potential for future market overhang from registered shares, introduces notable negative factors. The existing delinquency in payments to a research institute also presents a known financial risk.

Positives

• Successfully raised $450,500 in net proceeds, providing capital for business development, general working capital, and debt repayment.
• The pre-funded warrants have a nominal exercise price of $0.0001, indicating the majority of the capital was received upfront.
• The company granted piggy-back registration rights, which could facilitate future liquidity for the investor.

Negatives

• The issuance of 121,200 shares and warrants for 354,300 shares, plus 515,109 shares from a note conversion, represents significant dilution to existing shareholders.
• The investor's legal fees of $25,000 were deducted from the gross proceeds, reducing the net capital received by the company.
• The potential for future sales of the registered shares by the investor could create downward pressure on the stock price.

Risks

• Dilution Risk: The issuance of 121,200 common shares and warrants for 354,300 shares, along with 515,109 shares from a note conversion, significantly increases the outstanding share count, diluting existing shareholders.
• Market Overhang: The registration of the newly issued shares and warrant shares for resale creates a potential market overhang, as the investor may sell these shares, potentially putting downward pressure on the stock price.
• Public Information Failure Penalties: The company is subject to liquidated damages of $50,000 initially, and then $15,000 every seven calendar days, if it fails to timely file or maintain the effectiveness of the registration statement or comply with Rule 144 public information requirements.
• Litigation/Payment Delinquency: The company is aware of a delinquency in payments owed to Research Institute at Nationwide Children's Hospital pursuant to a settlement agreement dated June 7, 2022, which could lead to further legal or financial issues.
• Beneficial Ownership Limitation: The 4.99% beneficial ownership limitation (which can be increased to 9.99%) could restrict the investor's ability to fully exercise warrants immediately, but also means the investor could accumulate more shares over time.

Future Outlook

The company intends to use the proceeds for business development, general working capital, and debt repayment. It is also committed to filing a registration statement for the newly issued securities by September 26, 2025, or within 15 days of its Form S-4 becoming effective, and to maintain its Nasdaq listing.

Management Comments

• The Company understands and acknowledges the potentially dilutive effect of the Securities to the outstanding Common Stock of the Company.
• The Company further acknowledges that its obligation to issue the Securities pursuant to the terms of this Agreement is absolute and unconditional regardless of the dilutive effect that such issuance may have on the ownership interests of other shareholders of the Company.

Industry Context

This transaction is a standard private placement (PIPE) for a publicly traded biotechnology/healthcare company, common for raising capital for ongoing operations, R&D, and debt management. The awareness of a pending merger transaction (YOOV Group Holding Limited) suggests a strategic shift or expansion, and this capital raise could support that. The company's commitment to maintaining its Nasdaq listing is crucial for investor confidence and liquidity in the biotech sector.

Comparison to Industry Standards

• The use of pre-funded warrants with a nominal exercise price is a common structure in PIPE deals, allowing investors to commit capital upfront while deferring the actual share issuance, often to manage beneficial ownership limitations or facilitate future liquidity.
• The inclusion of robust registration rights, including piggy-back rights and liquidated damages for delays, is standard practice in private placements to ensure investors have a clear path to liquidity for their unregistered securities, aligning with typical investor protections seen in similar biotech financing rounds.
• The beneficial ownership limitation of 4.99% (with an option to increase to 9.99%) is a common feature in such agreements to prevent the investor from triggering certain reporting requirements (e.g., Schedule 13D) or control-related provisions, which is consistent with market practices for non-control investments.
• The specified penalties for "Public Information Failures" (e.g., failure to maintain Rule 144 compliance) are typical in these agreements, providing a financial incentive for the company to remain current with its SEC filings and ensure the investor's ability to resell shares.

Legal Proceedings

• The company is delinquent in payments owed to Research Institute at Nationwide Children's Hospital pursuant to a settlement agreement dated June 7, 2022.

Stakeholder Impact

• Shareholders: Existing shareholders will experience significant dilution due to the issuance of new common stock and warrants, as well as shares from a note conversion. The future sale of registered shares by the investor could also create downward pressure on the stock price.
• Creditors: The use of proceeds for debt repayment could positively impact creditors by reducing the company's outstanding liabilities.
• Management/Employees: The capital raise provides working capital, which supports ongoing business operations and potentially job security.

Next Steps

• Company to file a registration statement (Form S-1 or other appropriate form) for the 121,200 shares and 354,300 warrant shares by the earlier of 15 calendar days from SEC declaring Form S-4 effective or September 26, 2025.
• Company to use reasonable best efforts to have the registration statement declared effective within 30 calendar days of filing (75 days if SEC review).
• Company to maintain listing and trading of its Common Stock on the Principal Market (Nasdaq Capital Market).
• Company to comply with reporting requirements of the 1934 Act and Rule 144.
• Company to use proceeds for business development, general working capital, and debt repayment.

Key Dates

Recommendation

Keywords

Avalon GloboCare, ALBT, Private Placement, Securities Purchase Agreement, Pre-funded Warrants, Common Stock, Capital Raise, Equity Financing, SEC Filing, Form 8-K, Registration Rights, Dilution, Brown Stone Capital Ltd., Corporate Finance, Biotechnology, Healthcare